Multiple Sclerosis

Lord Willis of Knaresborough Excerpts

Thursday 13th October 2011 Lords Chamber

[Earl Howe]

My Lords, I take the noble Lord’s point. NICE is reviewing its clinical guideline. That is not due to be published until 2014. Although we strive to ensure that there is national guidance on the most commonly used medicines and treatments, there will always be instances where decisions have to be made locally. Under the NHS constitution, patients have the right to expect local decisions about the funding of medicines and treatments to be made rationally, following proper consideration of the evidence. We are emphasising to PCTs that they should do just that.

[Lord Willis of Knaresborough]

My Lords, one of the great problems—

[Baroness Gardner of Parkes]

My Lords—

--- Later in debate ---

[Earl Howe]

My Lords, new and innovative treatments for MS are being developed in a number of countries. It is quite clear that any new treatment of this kind should be subject to the rigours of the regulatory system before it is made available to NHS patients. Many of them will not have been fully tested to ensure efficacy and safety, but we will of course examine every novel and innovative treatment that has the potential to benefit patients.

[Lord Willis of Knaresborough]

My Lords—

[Lord Reid of Cardowan]

The Minister will be aware that the move from the large-scale commissioning of health services to smaller-scale commissioning carries a danger for those who will be deemed on the smaller scale not to have sufficient critical mass numbers to command attention. What do the Government intend to do to ensure that conditions such as MS and other chronic conditions are not endangered by that move to small-scale commissioning?